Parker Jenkins was still working on his PhD when he and his co-founder decided to do something most medical device startups avoid: skip the part where you sell hospitals expensive equipment.
Instead, Adialante—the Minneapolis-based company Jenkins launched with fellow University of Minnesota researcher Efraín Torres—plans to roll MRI scanners up to clinics in vans, charge a flat fee per scan, and move on. No million-dollar purchase orders. No construction crews ripping out walls to install electromagnetic shielding. Just show up, scan, bill insurance, repeat.
It's an audacious model, one that inverts decades of medical imaging economics. And it reflects a broader upheaval now reshaping the $7.1 billion global MRI market, where a clutch of startups and a few forward-thinking incumbents are betting they can drag one of medicine's most powerful diagnostic tools out of the hospital basement and into, well, just about anywhere.
The stakes are considerable. The American Cancer Society's data show that early detection can improve cancer survival rates dramatically—five-year survival for all cancers diagnosed between 2015 and 2021 reached 70%, up from 63% in the mid-1990s. But survival drops precipitously as stage at diagnosis advances. The calculus is brutally simple: catch it early, live longer. The obstacle has always been cost.
A conventional MRI installation runs between $1 million and $2 million for the machine alone. Total project costs—room construction, electromagnetic shielding, staff training—can hit $3 million. Annual service contracts add another $120,000 to $180,000. For most clinics, particularly those serving underserved populations, the economics simply don't work.
Now that's changing. And the shift is happening faster than many anticipated.
When Giants Move First
Here's something that doesn't happen often: the incumbents saw this coming.
Siemens Healthineers received FDA clearance in 2021 for its MAGNETOM Free.Max, a 0.55-tesla system that uses less than one liter of helium compared to the approximately 1,500 liters in traditional scanners. Philips went further with BlueSeal technology—a sealed 1.5-tesla magnet containing just seven liters of helium that eliminates the need for vent pipes and quench protection entirely.
Philips reported more than 1,500 BlueSeal systems installed globally by March 2025. Earlier figures from 2024 showed that 1,111 installations had saved over 1.9 million liters of helium. In the UK alone, 50 BlueSeal systems deployed by early 2025 had conserved more than 70,000 liters.
The timing proved prescient, perhaps more than even Philips anticipated. Reports in early 2026 warned of helium supply disruptions from Qatar threatening MRI services across Europe. The March 25, 2026 warnings underscored what the industry had quietly known for years: dependence on a volatile commodity was a strategic liability.
Helium-light systems cut installation costs—the University of Minnesota's Clinical and Translational Science Institute suggests reductions of around 30%—but they don't solve the fundamental problem of capital intensity. A clinic still needs to build a room, install shielding, and commit years to amortizing a multi-million-dollar asset.
That's where the insurgents come in.
Portability as Strategy
Hyperfine took a different approach entirely. Its Swoop system, a 0.064-tesla portable brain scanner initially cleared by the FDA in 2020, can be wheeled to a patient's bedside. Think rolling cart, not room-sized installation.
The company launched a next-generation Swoop powered by Optive AI software in 2025. FDA clearances for improved imaging and advanced diffusion-weighted imaging followed in December 2025, with CE and UKCA approvals for the upgraded system arriving in April 2026. Atlantic Health's Morristown Medical Center was among the first U.S. sites to deploy the new system last December.
A clinical study published in Neuroradiology on May 27, 2026, documented the use of ultra-low-field portable MRI in neuro-ICU and stroke units, demonstrating feasibility in acute-care settings where moving a critically ill patient to radiology is risky or impossible.
Synaptive Medical's Evry, a 0.5-tesla head-only system cleared in 2020, targets cranial imaging and stereotactic radiosurgery planning. Promaxo pursued an office-based niche with a prostate-focused platform that received 510(k) clearance in February 2025, aiming to bring MRI-guided interventions directly into urology clinics—the kind of place that would never justify a traditional installation.
These systems trade field strength for portability and cost. The images won't match a high-field scanner for every indication, but they're good enough for specific use cases: stroke triage, prostate detection, bedside monitoring. What they do, more importantly, is expand the accessible use cases. They bring MRI into settings where it was previously unthinkable.
The RF-Encoded Gambit
Efraín Torres finished his PhD in biomedical engineering at the University of Minnesota in 2024, working under MRI pioneer Michael Garwood. His work focused on something called "Frequency-modulated Rabi-Encoded Echoes," or FREE—a technique that uses RF-gradient encoding instead of traditional magnetic field gradients.
The first peer-reviewed paper on the approach appeared in Magnetic Resonance in Medicine in 2021, with subsequent work on fast AI-powered reconstruction published in 2024. By eliminating the B0 gradient coils, Torres and Jenkins believed they could cut hardware costs by around 30%, according to a March 14, 2024, statement from UMN's Clinical and Translational Science Institute.
But Adialante's business model is what really sets it apart from the usual medical device playbook.
Instead of selling machines, the company plans to operate what it calls a "mobile imaging clinic on wheels" that shows up at partner clinics on a scheduled basis. Clinics pay a flat per-scan fee, bill insurance, and keep the margin. No capital expenditure. No room construction. No multi-year depreciation schedule tying up balance sheets.
The company's website, updated in 2026, lists first deployments for Q4 2026 with "first clinics go live" shortly after. That's an aggressive timeline, even by startup standards.
Adialante participated in Y Combinator's Spring 2026 batch. YC's company profile claims $12.75 million in letters of intent, $30,000 in deposits, six clinics signed, and a plan to have "the first system scanning by demo day." The initial use case: prostate cancer.
That focus isn't accidental. The American Urological Association and Society of Urologic Oncology's 2023 Early Detection Guidelines—updated in 2026—support MRI before biopsy to improve detection of clinically significant disease, a moderate-strength recommendation backed by shared decision-making frameworks. In other words, there's a clinical rationale and a reimbursement pathway.
Adialante had raised roughly $3 million by June 2025, including a $1.18 million NSF SBIR Phase II award announced on June 19, 2025. Earlier SBIR Phase I work in 2023 focused on pediatric and affordable MRI applications. The company won the grand prize at the Walleye Tank life-sciences pitch competition on December 1, 2023.
YC's page for Adialante makes bold claims: "50% less hardware, 40% shorter, 80% lighter, whisper-quiet, no specialized infrastructure." Independent validation of those specs has not yet been published, but the proposition is compelling. If you can deliver MRI scans at a fraction of the cost and logistical burden, you potentially unlock enormous latent demand.
The question, as always, is execution.
Software Eating the Scan Time
Cost per machine is one lever. Throughput is another.
Conventional MRI scans can take 30 to 60 minutes, depending on the protocol. AI-powered reconstruction algorithms are compressing those times dramatically, and that has major economic implications.
Siemens' Deep Resolve reduced MRI exam times by more than 20% at NHS Fife in the UK, according to a November 2025 case report. GE HealthCare's AIR Recon DL claims 40% to 50% average scan-time reductions across anatomies in some deployments, per vendor materials from 2025-2026. Philips received FDA 510(k) clearance in 2025 for SmartSpeed Precise, a dual-AI software the company says can accelerate scans up to 3× and sharpen images by up to 80%—though those are vendor claims, not independently validated in randomized trials.
In April 2026, SimonMed Imaging announced the enterprise-wide deployment of AIRS Medical's SwiftMR across more than 170 centers. It's a vendor-neutral AI that layers on top of existing OEM reconstruction pipelines—a notable development in an industry where proprietary lock-in is the norm. FDA clearance for that interoperability came April 15, 2026. Studies cited by the companies suggest 30% to 50% scan-time reductions depending on anatomy and protocol.
Faster scans mean higher throughput. Higher throughput means lower cost per scan. Lower cost per scan makes MRI economically viable in more contexts. It's a flywheel, and it's starting to spin.
The Screening Problem
Consumer demand is clearly there, even if the evidence base is... murkier.
Prenuvo, which offers whole-body MRI scans for around $2,500, opened its first European clinic in London on November 24, 2025, joining a network of 27 clinics globally that had collectively performed more than 150,000 scans at that time. Ezra, SimonMed Longevity (starting around $899 in California as of June 2026), and Reveal MRI (which launched its "Reveal Total Scan" program in Henderson, Nevada, in April 2026) are all marketing preventive whole-body imaging to affluent consumers willing to pay out of pocket.
The problem is that the American College of Radiology isn't sold. The ACR issued a statement on April 17, 2023, advising against routine total-body MRI screening for asymptomatic average-risk individuals, citing insufficient survival outcome data and risks of false positives and overdiagnosis. That position remained unchanged as of 2026. The American Cancer Society echoed the caution in a May 2026 consumer explainer.
Whole-body MRI does have support in certain high-risk groups—patients with germline TP53 mutations and Li-Fraumeni syndrome, for instance, per a systematic review published in February 2024. But not for the general population walking into a mall clinic because they're worried.
Reimbursement reflects that ambiguity. CMS National Coverage Determination 177, updated effective March 7, 2026, does not cover routine or screening MRI without medical necessity. Diagnostic indications are covered per local coverage determinations and CPT coding, but payers aren't writing checks for asymptomatic scans. Abbreviated breast MRI for supplemental screening in patients with dense breasts shows higher cancer detection than digital breast tomosynthesis in retrospective cohorts, according to a study published in May 2024 covering data through May 2023. Yet payer coverage remains uneven.
So the consumer screening market is self-pay. And self-pay, at scale, requires prices low enough to attract volume beyond the wellness-obsessed wealthy.
That's where Adialante's mobile per-scan model becomes interesting. If a clinic can order an MRI the way it orders lab work—no capex, no room, just a flat fee—it changes the calculation for both the provider and the patient.
Not a Straight Path
Not every state makes any of this easy, of course.
Certificate-of-Need regulations in places like Mississippi require approval for both fixed and mobile MRI services, per rules revised through May 29, 2023. CON laws vary state by state, and navigating that patchwork adds friction and legal costs that startups don't always anticipate.
MRI systems are Class II devices. Manufacturers submit 510(k) premarket notifications referencing NEMA and ASTM safety standards. The FDA has cleared dozens of AI-enabled MRI reconstruction tools, with the agency's AI/ML-enabled device list updated as recently as March 27, 2026. Regulatory pathways are well-trodden, but they still take time and money—resources that burn quickly at early-stage companies.
Market incumbents, meanwhile, are not standing still. The U.S. mobile MRI services market already includes major operators like RAYUS, Shared Medical Services, DMS, and KMG, according to a 2026 Grand View Research analysis covering projections through 2030. These are established players with logistics networks, ACR accreditation (required for Medicare reimbursement since January 1, 2012, under MIPPA), and longstanding relationships with hospital systems.
A startup promising a novel RF-encoded scanner needs to prove not just technical feasibility but operational reliability at scale. That's a different challenge entirely.
The Bigger Picture
The American Cancer Society estimates 2,114,850 new cancer cases and 626,140 deaths in 2026. A modeling study published in October 2025 suggested that annual multi-cancer early detection blood testing could reduce stage IV diagnoses by 45% over a decade, illustrating the value of stage-shift. MRI could play a confirmatory or complementary role in multi-modal early detection strategies—particularly if costs drop enough to justify broader use.
Adialante's Q4 2026 deployment timeline is aggressive, even optimistic. The company will need to demonstrate that its RF-encoded system produces diagnostic-quality images, that its mobile logistics work in practice, that clinics actually bill and collect from payers for the scans, and that the unit economics hold. Those are not trivial hurdles.
But if the model works for prostate imaging, it could extend to other anatomies. Torres and Jenkins have indicated a stepwise roadmap from head and orthopedic applications to full-body scans, per a March 14, 2024, UMN CTSI feature.
The broader trend, though, is undeniable. MRI is shedding helium, shrinking in size, getting faster with AI, and moving out of hospital radiology departments. Portable systems are already scanning in ICUs. Office-based systems are targeting urology and neurology practices. Mobile units are showing up in clinic parking lots.
The global MRI market was valued at $7.1 billion in 2024 and is projected to reach approximately $10.3 billion by 2030. That growth won't come from selling more $2 million boxes to tertiary hospitals. It will come from bringing MRI to places it has never been economically viable before.
Whether Adialante becomes a category leader or a cautionary tale, the race to reinvent MRI has begun. The winner will be whoever figures out how to deliver diagnostic-quality imaging at a price point and convenience level that unlocks the latent demand for early detection.
The market is there. The technology is advancing. The question, as always with startups, is execution. And the clock is ticking.
